These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 31373443)

  • 1. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
    Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
    Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
    Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
    Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
    Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
    Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
    Jin B; Wang C; Li J; Du X; Ding K; Pan J
    Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
    Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
    BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miRNAs in chronic myeloid leukemia: small molecules, essential function.
    Litwińska Z; Machaliński B
    Leuk Lymphoma; 2017 Jun; 58(6):1297-1305. PubMed ID: 27736267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML.
    Toda J; Ichii M; Oritani K; Shibayama H; Tanimura A; Saito H; Yokota T; Motooka D; Okuzaki D; Kitai Y; Muromoto R; Kashiwakura JI; Matsuda T; Hosen N; Kanakura Y
    Oncogene; 2020 Aug; 39(34):5601-5615. PubMed ID: 32661325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia.
    Zhou J; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Dai W; Wang Y; Jin Y; Pan J
    Clin Cancer Res; 2018 Jan; 24(1):145-157. PubMed ID: 29070525
    [No Abstract]   [Full Text] [Related]  

  • 10. Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib.
    Avilés-Vázquez S; Chávez-González A; Hidalgo-Miranda A; Moreno-Lorenzana D; Arriaga-Pizano L; Sandoval-Esquivel MÁ; Ayala-Sánchez M; Aguilar R; Alfaro-Ruiz L; Mayani H
    Cancer Med; 2017 Dec; 6(12):2942-2956. PubMed ID: 29030909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.
    Scott MT; Korfi K; Saffrey P; Hopcroft LE; Kinstrie R; Pellicano F; Guenther C; Gallipoli P; Cruz M; Dunn K; Jorgensen HG; Cassels JE; Hamilton A; Crossan A; Sinclair A; Holyoake TL; Vetrie D
    Cancer Discov; 2016 Nov; 6(11):1248-1257. PubMed ID: 27630125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.
    Abraham SA; Hopcroft LE; Carrick E; Drotar ME; Dunn K; Williamson AJ; Korfi K; Baquero P; Park LE; Scott MT; Pellicano F; Pierce A; Copland M; Nourse C; Grimmond SM; Vetrie D; Whetton AD; Holyoake TL
    Nature; 2016 Jun; 534(7607):341-6. PubMed ID: 27281222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening and identification of key genes in imatinib-resistant chronic myelogenous leukemia cells: a bioinformatics study.
    Zhang H; Wang P; Song T; Bonnette UL; Zhang Z
    Hematology; 2021 Dec; 26(1):408-414. PubMed ID: 34053416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
    Woessner DW; Lim CS
    Mol Pharm; 2013 Jan; 10(1):270-7. PubMed ID: 23211037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
    Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
    Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia.
    Čokić VP; Mojsilović S; Jauković A; Kraguljac-Kurtović N; Mojsilović S; Šefer D; Mitrović Ajtić O; Milošević V; Bogdanović A; Đikić D; Milenković P; Puri RK
    Blood Cells Mol Dis; 2015 Dec; 55(4):373-81. PubMed ID: 26460262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6.
    Zhou M; Zhang X; Liu C; Nie D; Li S; Lai P; Jin Y
    Oncogene; 2021 May; 40(20):3564-3577. PubMed ID: 33931742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
    Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.